繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗肿瘤药 >> 新药动态 >> 保尔佳针配合手术、化疗治疗消化道癌的临床观察

保尔佳针配合手术、化疗治疗消化道癌的临床观察

2009-09-03 09:57:16  作者:新特药房  来源:中国新特药网  浏览次数:73  文字大小:【】【】【
简介: 目的 :观察保尔佳配合手术、化疗治疗消化道癌的疗效。方法 :将 48例消化道癌随机分为两组 ,手术、常规化疗 +保尔佳组 30例 ,其中胃癌 13例 ,结肠癌 10例 ,直肠癌 7例。手术、常规化疗组 (对 ...
关键字:保尔佳针

 
 
目的 :观察保尔佳配合手术、化疗治疗消化道癌的疗效。方法 :将 48例消化道癌随机分为两组 ,手术、常规化疗 +保尔佳组 30例 ,其中胃癌 13例 ,结肠癌 10例 ,直肠癌 7例。手术、常规化疗组 (对照组 ) 18例 ,其中胃癌9例 ,结肠癌 6例 ,直肠癌 3例。疗程 4~ 8周。结果 :保尔佳组治疗有效率 6 0 .0 % ,对照组有效率 5 1.5 % (P <0 .0 5 ) ;保尔佳组消化道反应、恶心呕吐、食欲下降的发生率为 2 6 .7% ,对照组为 72 .2 % (P <0 .0 1) ;保尔佳组肝功能异常的发生率 6 .7% ,对照组 2 2 .2 % (P <0 .0 1) ;保尔佳组白细胞下降到 3.5× 10 9/L以下为 13 .3% ,对照组为 38.9%(P <0 .0 1)。结论 :保尔佳配合手术、化疗能明显减轻化疗的不良反应 ,提高治愈率和生存质量
【作者单位】:山西医科大学第一医院普外科!太原市030001(赵瑛);山西省第二人民医院(郭振伟)
【关键词】:消化道癌;保尔佳;生存质量
【正文快照】:
消化道癌经手术治疗后配合化疗是提高疗效、防止复发的重要手段 ,但许多患者在治疗过程中 ,终因药物毒副作用 ,如白细胞降低、恶心、呕吐、食欲下降、肝功能异常等而被迫终止或暂停用药。我院自1997年 12月至 1999年 10月对 30例消化道癌根治性切除术后患者用保尔佳配合化疗 ,

Objective:To observe the therapeutic effect on patients with cancer of digestive tract of Polyerga in combination with chemotherapy.Methods:Forty eight cases of digestive tract cancer were randomly divided into two groups. Thirty cases were treated with Polyerga in combination with surgery and regular chemotherapy. Thirteen were carcinoma of stomach, seventeen were carcinoma of colon and seven were rectal carcinoma. Eighteen cases (the control group)were treated only with operation and chemotherapy. In this group nine were carcinoma of stomach, six were carcinoma of colon and three were rectal carcinoma. Both groups were treated for four to eight weeks.Results:Good effect was observed 60% of Polyerga group while in the control group it was 51.1% ( P <0.05). The incidence rate of digestive tract reaction, nausea and vomiting, and the lose of appetite was 26.7%, while in the control group it was 72.2% ( P <0.01). The abnormal incidence rate of liver function in Polyerga group was 6.7% and in the control group it was 22.2% ( P <0.01). Leucocysemia below 3500/mm3 was found in 13.3% of the Polyerga group and 38.9% ( P <0.01)in the control group.Conclusion:Polyerga combined with operation and chemotherapy can alleviate the side effect of chemotherapy and elevate the effect of treatment and the quality of life of patients with cancer in digestive tract.
【Keyword】:Digestive canal cancer Polyerga Quality of life

责任编辑:admin


相关文章
 

最新文章

更多

· Sensipar被FDA批准用于治...
· Perjeta(pertuzumab,帕...
· ImMucin新型癌症疫苗-可...
· 2011年获FDA批准上市的抗...
· Supect(拉多替尼胶囊,R...
· FDA批准前列腺癌药物(l...
· 磷雌酚钠(Fostestrol S...
· 易普利姆玛(Ipilimumab)...
· Revlimid(Lenalidomide,...
· FDA批准Erivedge(vismod...

推荐文章

更多

· Sensipar被FDA批准用于治...
· Perjeta(pertuzumab,帕...
· ImMucin新型癌症疫苗-可...
· 2011年获FDA批准上市的抗...
· Supect(拉多替尼胶囊,R...
· FDA批准前列腺癌药物(l...
· 磷雌酚钠(Fostestrol S...
· 易普利姆玛(Ipilimumab)...
· Revlimid(Lenalidomide,...
· FDA批准Erivedge(vismod...

热点文章

更多